



J. B. Chemicals & Pharmaceuticals Limited

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2010

(` in Lacs)

Sr. No.	PARTICULARS	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
		31/12/2010 (Unaudited)	31/12/2009 (Unaudited)	31/12/2010 (Unaudited)	31/12/2009 (Unaudited)	31/03/2010 (Audited)
1	a) Net Sales (Net of excise)	21,667.77	19,807.14	60,868.88	50,434.81	67,006.45
	b) Other Operating Income	548.04	396.39	1,415.52	1,095.78	1,532.87
	Total Income	22,215.81	20,203.53	62,284.40	51,530.59	68,539.32
2	Expenditure					
	a) (Increase)/Decrease in Stock in Trade & WIP	(898.94)	987.56	(321.24)	(53.33)	(321.94)
	b) Consumption of Raw Materials	5,999.03	3,665.59	15,780.39	12,440.57	16,126.49
	c) Purchase of Traded Goods	865.26	603.61	3,540.05	3,010.24	4,410.23
	d) Employees Cost	3,422.20	2,399.80	8,823.34	7,079.97	9,846.93
	e) Depreciation	602.30	541.00	1,697.30	1,596.00	2,122.25
	f) Sales Promotion & Publicity	3,356.41	4,251.88	7,554.04	6,416.26	8,752.12
	g) Exchange Fluctuation Suffered (Gain)/Loss	(37.91)	(204.48)	216.85	1,279.80	1,516.20
	h) Other Expenditure	4,602.47	3,860.73	12,707.25	10,656.34	14,542.43
	Total	17,910.82	16,105.69	49,997.98	42,425.85	56,994.71
3	Profit from operations before Other Income & Interest (1-2)	4,304.99	4,097.84	12,286.42	9,104.74	11,544.61
4	Other Income	140.85	22.42	378.01	24.95	193.52
5	Profit before Interest (3+4)	4,445.84	4,120.26	12,664.43	9,129.69	11,738.13
6	Interest	158.84	158.45	547.01	727.02	894.51
7	Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)	4,287.00	3,961.81	12,117.42	8,402.67	10,843.62
8	Exchange Fluctuation Gain / (Loss)	304.43	(197.83)	194.80	571.48	1,250.80
9	Profit from Ordinary Activities Before Tax (7-8)	4,591.43	3,763.98	12,312.22	8,974.15	12,094.42
10	Tax Expenses :					
	Current Tax	918.00	914.52	2,462.00	1,600.99	2,067.00
	MAT Credit Entitlement	(70.00)	-	(410.00)	-	-
	Deferred Tax	(68.89)	(106.77)	(80.35)	16.23	79.48
	Short/(Excess) Provision for Taxation for prior year	-	-	(2.34)	(45.14)	(151.79)
11	Profit from Ordinary Activities After Tax (9-10)	3,812.32	2,956.23	10,342.91	7,402.07	10,099.73
12	Paid-up Equity Share Capital (Face Value Rs. 2/- per share)	1,689.92	1,686.53	1,689.92	1,686.53	1,686.53
13	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	-	-	59,650.61
14	Earnings Per Share (EPS)					
	a) Basic (Not annualised)	4.52	3.51	12.25	8.78	11.98
	b) Diluted (Not annualised)	4.51	3.51	12.23	8.78	11.98
15	Public Shareholding					
	No. of shares	37,642,460	37,473,610	37,642,460	37,473,610	37,470,610
	% of shareholding	44.55	44.43	44.55	44.43	44.44
16	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	-	-	-	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	b) Non-encumbered					
	Number of shares	46,853,590	46,852,740	46,853,590	46,852,740	46,855,740
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	55.45	55.57	55.45	55.57	55.56

NOTES :

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at in meeting held on January 13, 2011.
2. The Statutory Auditors have carried out a limited review of the above financial results for the quarter and nine months ended on December 31, 2010.
3. There were no outstanding complaints from investors at the beginning of the quarter. The Company received 13 complaints from the investors during the quarter, which have been disposed of during the quarter.
4. The Company is engaged in a single segment of activity namely, "Pharmaceuticals".
5. During the quarter, the company allotted 57,825 equity shares against exercise of stock options.
6. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary

For J.B. CHEMICALS & PHARMACEUTICALS LTD.

Place : Mumbai
Date : January 13, 2011

J.B.MODY
CHAIRMAN & MANAGING DIRECTOR